Showing results (1641-1650 of 2,171) with videos related to

Sort By:
Pageof 218
Acta Dermato-Venereologica|September 5, 2024
Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)April W Armstrong, Elisabeth Riedl, Patrick M Brunner, et al.
Plos One|May 10, 2024
Shared decision-making in psoriasis care: Evaluation of how patients' perception of clinicians' delivery of care changes by age and sexRobin Kikuchi, Paige Kingston, Audrey Hao, et al.
The American Journal of Cardiology|December 1, 2001
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-TrialB G Angeja, J H Alexander, R Chin, et al.
Transplantation|March 18, 2003
Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrheaBart D Maes, Ignace Dalle, Karen Geboes, et al.
American Heart Journal|June 2, 2015
Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trialPaul W Armstrong, Yinggan Zheng, Cynthia M Westerhout, et al.
Journal of the American College of Cardiology|March 27, 2001
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromesM C Bahit, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|November 1, 1995
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary ArteriesG I Barbash, J Reiner, H D White, et al.
Science (New York, N.Y.)|June 30, 2012
The tides of TitanLuciano Iess, Robert A Jacobson, Marco Ducci, et al.
Circulation|November 3, 1998
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb InvestigatorsP W Armstrong, Y Fu, W C Chang, et al.
American Heart Journal|November 13, 2019
Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular diseaseJay S Shavadia, Yinggan Zheng, Jennifer B Green, et al.
Pageof 218